TS LINES (02510) intends to sell ships and lease ships.
Texi Shipping (02510) announced that on January 22, 2026, the seller (a wholly-owned subsidiary of the company) entered into a sales agreement with the buyer to sell the vessel (TS SHENZHEN, a container ship) to the buyer for a price of 23 million US dollars (equivalent to approximately 179.4 million Hong Kong dollars).
TS LINES (02510) announced that on January 22, 2026, the seller (a wholly-owned subsidiary of the company) entered into a sale agreement with the buyer to sell the vessel TS SHENZHEN, a container ship, for a price of $23 million (equivalent to approximately $179.4 million Hong Kong dollars).
The Board believes that the Group will realize immediate financial benefits from the sale. Additionally, the sale will help the Group reduce costs associated with owning the vessel, including but not limited to crew, insurance, and maintenance costs; optimize its fleet size without impacting its ability to meet future chartering needs; and raise additional funds for capital expenditures, investments, and other strategic businesses.
On January 22, 2026, TS Singapore (a wholly-owned subsidiary of the company), the seller, and the buyer entered into a vessel charter agreement with a term from January 24, 2026, to March 31, 2026.
In the past, TS Singapore has been leasing the vessel from the seller under various charter agreements (including time charter agreements) since January 2025, in order to meet market demand for various trade routes' capacity changes, and operate trade routes with the appropriate vessel capacity. In January 2026, the vessel was sold from the seller to the buyer, and the company believes that maintaining this leasing arrangement for transition purposes is beneficial to avoid disruption to its normal business operations during the short period of the vessel charter agreement.
Related Articles

LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.
LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


